BOSTON, Dec. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company looks forward to a prosperous 2010, following a solid year in 2009, due in great part to its MammoView(TM) instrument line.
In the closing months of 2009, Solos Endoscopy, Inc. has taken the initial steps to obtain the CE Mark for its MammoView(TM) line of surgical endoscopy instruments. This will allow the MammoView(TM) line to be sold throughout the European Economic Union (EEU), which according to a 2009 report published by Frost & Sullivan represents $94 Billion, or 30%, of the worldwide demand for medical instruments.
Solos' focus is to strengthen its domestic market share in the industry through the implementation of several strategies in the New Year. In addition, Solos will continue building product awareness and has retained the services of Advertising Associates International to manage its 2010 marketing, promotional and advertising campaign. Finally, the Company plans to expand its research and development efforts to develop new instrumentation to better assist the physician primarily in the area of breast endoscopy.
"We are excited about the progress that Solos has made in 2009. We look forward to increasing our sales revenues with the implementation of our product awareness campaign while at the same time increasing our research and development efforts," stated Bob Segersten, President of Solos Endoscopy, Inc.
For more details on Solos Endoscopy, Inc's accomplishments in 2009 and expectations for 2010 please visit: www.solosendoscopy.com.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2009 PR Newswire.
All rights reserved